Purpose: The purpose of this study was to compare the dosimetric parameters of two radiotherapy techniques for the cervical cancer treatment: three-dimensional conformal radiotherapy and arc-therapy.
Introduction
According to the World Health Organization (WHO), cervical cancer is the fourth most common cancer in women worldwide [1] . In 2018, 570000 new cases were estimated with 311000 cases of death. 85% of these cases were in lowincome countries. Cervical cancer is the second most common cancer in Moroccan females [2] . The management of locally advanced cervical cancer (Ib2-IVA) is based on concomitant chemoradiotherapy and endocavitary brachytherapy [3] . Adjuvant radiotherapy with or without concomitant chemotherapy is indicated whenever there are anatomo-pathological risk factors in the surgical specimen [4] . When brachytherapy is not feasible (non-catheterizable cervix, large residual tumor, patient's refusal...) an additional 20 to 24 Gy by external radiotherapy is an alternative [5] .
Conformational radiotherapy has allowed loco-regional control of the disease at the expense of digestive, bladder and hematopoietic toxicity [6] . Concomitant chemotherapy aggravates acute and late grade III and IV toxicity by 34% and 21%, respectively [7] . In the 2000s, Intensity-Modulated RadioTherapy (IMRT) reduced digestive and hematologic toxicity while maintaining a consistent coverage of the planning target volume [8] . Indeed, the study by Roeske coverage of PTV (p = 0.01), better intestinal savings (p = 0.01) and a reduction in volume receiving 20 Gy (p <0.001).
The VMAT also reduced processing time and monitor units (p = 0.0001) [8] . 
Materials and Methods
The medical records of 20 patients supported for uterine Gy is added to PTV2 by arc-therapy. The primary objective of the constraints was a good coverage of the planning target volumes by 95% reference isodose. Dose constraints for OARs are summarized in Table 1 . 
Monitoring and toxicity
During radiotherapy, a weekly consultation was conducted to evaluate the toxicity and acute complications of the treatment. Then, at the end of the first series, a clinical examination and an MRI were done. Once the brachytherapy was considered not feasible the 2nd series of radiotherapy was performed. A follow-up consultation was conducted every three months in the first two years and then every six months for five years. An MRI of control was requested at the first consultation then annually.
Results

For the 50 Gy series
The coverage of the planning target volume by 3DRT and VMAT is summarized in Table 2 . These results show that there is no difference between these two techniques. For, the homogeneity index was close to 0 (0.068 for 3DRT vs 0.090 for VMAT). As for the conformity index, it tended to 1 (0.99 for 3DRT vs. 0.98 for VMAT) with a slightly significant p = 0.039. For organs at risk, Arc-therapy had reduced the bladder irradiated volumes by doses greater than 50 Gy (p = 0.01). It allowed a better rectal saving concerning volumes V 30 , V 40 and V 50 significantly ( 
For the 70 Gy series
The addition of a 20 Gy complement dose by arc-therapy after 50 Gy by 3DRT allowed PTV2 coverage to be similar to that achieved by arc-therapy alone ( Table 4 ). In addition, this supplement did not bring any significant benefit to the organs at risk. Indeed, the Arc-therapy allowed a better bladder, rectal and small bowels savings with clearly significant p ( 
Evolutions and toxicities
All patients completed their radiotherapy protocol. No acute complications of grade III or IV were recorded during the first series. A case of cystitis and neutropenia grade III has been reported after 50 Gy in a patient's FIGO stage IVA.
The median follow-up after the end of radiotherapy was 45 months. The progression was marked by a locoregional recurrence rate of 30% (25% in the Arc-therapy arm vs 37% in the 3DRT arm) and by a metastasis of 8.33% in the arctherapy arm. Locoregional and metastatic relapses were more frequent in stage III compared to stage II (46.15% vs 33.33%). A case of chronic grade III cystitis was reported in a patient's FIGO stage IVA. We also recorded a death rate of 30% (25% in the Arc-therapy arm vs 37% in 3DRT arm).
Discussions
In a Japanese study, Roeske et al. (2003) compared arctherapy with 3DRT. This study did not report any significant difference in terms of coverage of the PTV (D 95% = 94.5% vs 95.1% and D 98% = 102.1% vs 102%). For the complement by arc-therapy on the high-risk CTV, it recommended a PTV greater than one centimeter considering the important mobility of the uterus in intra and inter-fractions [12] .
Several other studies have confirmed these results [13, 14, 15] . In our series the complement by arc-therapy after 50Gy was done with a 1 cm PTV2 around the high risk CTV. The results found are similar in both arms. They allow a homogeneous coverage and a good conformation of the target volumes.
In our series the complement by external radiotherapy was decided after the end of the 50Gy and consequently it was not possible to deliver on the tumor volume at high risk that 
Conclusion
This work aims to compare dosimetry treatment plans by conformal radiotherapy and arc-therapy for cervical cancer.
The results obtained show that the arc-therapy allows a better conformity, coverage and homogeneity of the PTV. It also allows better preservation of organs at risk such as the rectum; bladder and small bowel thus reducing the acute and late toxicities of treatment. Arc-therapy would be a better therapeutic alternative when brachytherapy is not feasible. It could improve the patient's life quality.
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